Resources for pelvic nodal volume in prostate hypofrac?

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

Chartreuse Wombat

Full Member
7+ Year Member
Joined
May 7, 2014
Messages
1,486
Reaction score
2,987
Dose constraints below from UK trial of moderate hypo


1592938590814.png
 
  • Like
Reactions: 3 users

KHE88

LITERALLY costing lives.
Removed
2+ Year Member
Joined
May 15, 2018
Messages
723
Reaction score
1,188
I don't think anybody knows optimal volumes. I recently saw a node of Cloquet failure. Most probably wouldn't have covered that.
Is there even consensus if nodes are regional disease in prostate or not? Why are we electively covering non-regional sites?
So where exactly is the regional at-risk areas worth electively covering in prostate? Do we have a good answer for this yet? I keep looking but I can't find one.

I believe in treating nodes in higher risk patients and tend to be a bit more generous due to lack of good consensus and plenty of reported failures outside of tradiational nodal volumes in other pelvic cancers

As far as dose painting...
I have done both 60/20 with 44/20 and 70/28 with 50.4/28. I think the question you are asking is what to cover. If there are recent consensus guidelines I'm not aware of, I'd be interested too.
 

taserlaser

From the Great White North 🇨🇦
5+ Year Member
Joined
Feb 17, 2017
Messages
385
Reaction score
596
I don't think anybody knows optimal volumes. I recently saw a node of Cloquet failure. Most probably wouldn't have covered that.
Is there even consensus if nodes are regional disease in prostate or not? Why are we electively covering non-regional sites?
So where exactly is the regional at-risk areas worth electively covering in prostate? Do we have a good answer for this yet? I keep looking but I can't find one.

I believe in treating nodes in higher risk patients and tend to be a bit more generous due to lack of good consensus and plenty of reported failures outside of tradiational nodal volumes in other pelvic cancers

As far as dose painting...
I have done both 60/20 with 44/20 and 70/28 with 50.4/28. I think the question you are asking is what to cover. If there are recent consensus guidelines I'm not aware of, I'd be interested too.

The docs where I’m at use a lot of 44/20 for nodal volumes, or 25/5 for 5 fr SBRT cases. Not sure how much evidence if any for those, but it’s done.

I’ve also seen a draft version of an updated society atlas/guideline for prostate nodes based on PSMA data/recurrences which should hopefully be out soon (well, pre covid, who knows how much things got delayed), which may affect where people target as well
 
  • Like
Reactions: 1 user

scarbrtj

I Don't Like To Bragg
5+ Year Member
Joined
Dec 18, 2015
Messages
3,216
Reaction score
4,922
I don't think anybody knows optimal volumes. I recently saw a node of Cloquet failure. Most probably wouldn't have covered that.
Is there even consensus if nodes are regional disease in prostate or not? Why are we electively covering non-regional sites?
So where exactly is the regional at-risk areas worth electively covering in prostate? Do we have a good answer for this yet? I keep looking but I can't find one.

I believe in treating nodes in higher risk patients and tend to be a bit more generous due to lack of good consensus and plenty of reported failures outside of tradiational nodal volumes in other pelvic cancers

As far as dose painting...
I have done both 60/20 with 44/20 and 70/28 with 50.4/28. I think the question you are asking is what to cover. If there are recent consensus guidelines I'm not aware of, I'd be interested too.
Again, as I'm oft wont to say, "I might be hallucinating" but if you go back and look at some of the old, pre-1980's classic surgical prostate cancer node involvement literature, the inguinal nodes were usually the first or second most commonly involved nodal met site. A kind of "inconvenient truth" maybe. But I never heard tell of rad onc nodal coverage guidelines explicitly advocating covering the inguinals in prostate cancer. It's a reason (apart from the really lackluster clinical data showing ENI helps, of course) I'm not big on ENI in prostate. Sorry, Mack.
 
  • Like
Reactions: 2 users

elementaryschooleconomics

Mask on, Aquaplast, Mask off.
2+ Year Member
Joined
Nov 2, 2019
Messages
2,788
Reaction score
11,359
Again, as I'm oft wont to say, "I might be hallucinating" but if you go back and look at some of the old, pre-1980's classic surgical prostate cancer node involvement literature, the inguinal nodes were usually the first or second most commonly involved nodal met site. A kind of "inconvenient truth" maybe. But I never heard tell of rad onc nodal coverage guidelines explicitly advocating covering the inguinals in prostate cancer. It's a reason (apart from the really lackluster clinical data showing ENI helps, of course) I'm not big on ENI in prostate. Sorry, Mack.

Did you just pull out a YouTube video with 695 views???
 
  • Like
Reactions: 1 users

ramsesthenice

Full Member
10+ Year Member
Joined
Dec 2, 2011
Messages
1,332
Reaction score
2,464
I'm not big on ENI in prostate. Sorry, Mack.

Me neither. But I am doing hypofrac in patients with positive nodes from time to time. I don't have a source to point to but I essentially treat the nodes the same as I always would and treat them to 45-50 Gy in 25 fractions as an SIB. The prostate and gross nodes get what they get with they hypofrac regimen. I have yet to really notice any difference in acute toxicity with this than I did with conventional. I have never, nor do I know of anyone that hypofractionates the uninvolved nodes.
 

evilbooyaa

Full Member
Staff member
Volunteer Staff
10+ Year Member
Joined
Oct 10, 2011
Messages
8,040
Reaction score
9,401
Not doing ENI really ever.

N+ patients can consider just taking to prescription dose I suppose, although I would worry about toxicity of 70/28 next to bowel and thus likely go with some sort of SIB plan in 25 fractions.
 

Mandelin Rain

Full Member
10+ Year Member
Joined
Apr 21, 2011
Messages
3,171
Reaction score
7,860
Again, as I'm oft wont to say, "I might be hallucinating" but if you go back and look at some of the old, pre-1980's classic surgical prostate cancer node involvement literature, the inguinal nodes were usually the first or second most commonly involved nodal met site. A kind of "inconvenient truth" maybe. But I never heard tell of rad onc nodal coverage guidelines explicitly advocating covering the inguinals in prostate cancer. It's a reason (apart from the really lackluster clinical data showing ENI helps, of course) I'm not big on ENI in prostate. Sorry, Mack.
Takeaway from video: I think Mack REALLY likes knowing that "every radiation resident has to memorize the Roach Equation because it's on the test."

Did love the actual randomized national trial that examined this question, "we're not going to spend a lot of time on this [switches slide after 2 seconds (shows that pelvic radiation had the best AND worst outcomes with prostate only arms directly between)]." {Spends an hour belaboring surgical data and retrospective data}.

Radiation oncology in a nutshell. Forget the data, I've got dogma.
 
  • Like
  • Haha
Reactions: 1 users

scarbrtj

I Don't Like To Bragg
5+ Year Member
Joined
Dec 18, 2015
Messages
3,216
Reaction score
4,922
Takeaway from video: I think Mack REALLY likes knowing that "every radiation resident has to memorize the Roach Equation because it's on the test."

Did love the actual randomized national trial that examined this question, "we're not going to spend a lot of time on this [switches slide after 2 seconds (shows that pelvic radiation had the best AND worst outcomes with prostate only arms directly between)]." {Spends an hour belaboring surgical data and retrospective data}.

Radiation oncology in a nutshell. Forget the data, I've got dogma.
This is the well known reaction everyone had after Mack explained what RTOG 9413 meant in ASTRO plenary the year it came out.
 
  • Haha
Reactions: 1 user

taserlaser

From the Great White North 🇨🇦
5+ Year Member
Joined
Feb 17, 2017
Messages
385
Reaction score
596
Me neither. But I am doing hypofrac in patients with positive nodes from time to time. I don't have a source to point to but I essentially treat the nodes the same as I always would and treat them to 45-50 Gy in 25 fractions as an SIB. The prostate and gross nodes get what they get with they hypofrac regimen. I have yet to really notice any difference in acute toxicity with this than I did with conventional. I have never, nor do I know of anyone that hypofractionates the uninvolved nodes.

What I had mentioned above was explicitly uninvolved nodes in high risk patients. So there are some
 

ramsesthenice

Full Member
10+ Year Member
Joined
Dec 2, 2011
Messages
1,332
Reaction score
2,464
What I had mentioned above was explicitly uninvolved nodes in high risk patients. So there are some

I am sure there are. I meant I don't personally know anyone so I can't speak to what folks are doing or how well it is going :). I have no doubt in my mind that moderate hypofrac (in the 2-3 range) would probably go ok to the nodal volumes. I just haven't pulled the trigger yet. Im in the Scar camp and don't treat nodes that often in all but the highest risk N0 patients.
 
  • Like
Reactions: 1 user

Palex80

RAD ON
15+ Year Member
Joined
Dec 17, 2007
Messages
2,991
Reaction score
3,360
Here are some for SBRT:
 
Top